HighTide Therapeutics Inc (HKSE:02511) Share Price

Company Profile

Business description
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.
Contact
Building D, Guangdong
Floor 9 to 10, Fubao Community, Futian District
Shenzhen-Hong Kong Science and
Technology Innovation Cooperation Zone
Shenzhen518112
CHN
T: +86 75526626253
https://www.hightidetx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
70

Recommended

We were wrong when we thought last quarter would be hard to top.

Dan Romanoff, CPA | 31 July 2025

These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.

Susan Dziubinski | 30 July 2025

We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.

Shaun Ler | 30 July 2025

Index	Last price	Change	% Change
All Ordinaries	8,936.40	62.60	-0.70%
CAC 40	7,771.97	89.99	-1.14%
DAX 40	24,065.47	196.75	-0.81%
Dow JONES (US)	44,130.98	330.30	-0.74%
FTSE 100	9,132.81	4.13	-0.05%
HKSE	24,742.24	31.09	-0.13%
NASDAQ	21,122.45	7.23	-0.03%
Nikkei 225	40,979.46	90.36	-0.22%
NZX 50 Index	12,769.32	54.42	-0.42%
S&P 500	6,339.39	23.51	-0.37%
S&P/ASX 200	8,680.80	62.00	-0.71%
SSE Composite Index	3,566.62	6.58	-0.18%